H.C. Wainwright analyst Raghuram Selvaraju downgraded CervoMed (CRVO) to Neutral from Buy without a price target saying the “disappointing” neflamapimod clinical data “creates uncertainty.” The cites the RewinD-LB study failure for the downgrade.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO: